Under the leadership of Dr. Frank Huang, Chairman and CEO, BioGate disclosed that their in-house research and development team has engineered BGX by integrating cutting-edge multi-platform technologies in biochemistry, immunology, and molecular biology. Preliminary studies have demonstrated BGX's potential in curtailing tumor growth, preventing metastatic proliferation, and notably improving survival rates in animal models injected with human pancreatic cancer cells.

This breakthrough is hailed as a crucial global milestone in pancreatic cancer therapy. With the current grim prognosis for pancreatic cancer patients, due to late diagnoses and limited effective treatments, BGX offers a beacon of hope. Traditional chemotherapy regimens, often fraught with severe side effects, fall short in significantly extending patients' lives. In contrast, BGX targets and disrupts cancer cell signal pathways with minimal toxicity, paving the way for a non-invasive treatment option that could dramatically enhance patient outcomes and life expectancy.

BioGate is poised to initiate Phase I clinical trials, pending approvals from the Taiwan Food and Drug Administration (TFDA) and the U.S. FDA. This move signifies a major step forward in making this pioneering treatment available to pancreatic cancer patients both in Taiwan and globally, where the disease annually impacts half a million people.

Dr. Huang also spotlighted the broader implications of BGX's success, suggesting its potential applicability in combating other cancer types, including lung, colorectal, and breast cancers, among others. BioGate's ongoing commitment to innovative drug development aims to extend beyond pancreatic cancer, offering new avenues for treating various malignancies and associated conditions like cachexia.

Furthermore, BioGate is actively pursuing strategic partnerships with stakeholders across the pharmaceutical industry, academia, and research institutions. These collaborations are designed to facilitate the co-development of novel therapeutics and clinical trials, with the goal of exploring international markets and enhancing the company's operational strength and value.